This thesis not only provided a picture of IPC in both Dongguan city and Mainland China, but also objectively and comprehensively evaluated the current status of outcome indicator surveillance and the implementation of IPC strategies in China.
The results allowed comparison with national and international data sources; and thus, contributed Chinese data to the global health perspective.
Our research established a good example for Asian countries to evaluate and improve outcome indicators, particularly for prospective AMR surveillance. We applied a standardised protocol (EARS-Net protocol) for the AMR burden estimation, which allows for geographical comparisons between Asia and Europe. Although our
findings in this research could not be representative for the situation of Asia, to variable degrees, it can elevate the visibility of IPC and promote the implementation of the outcome indicator surveillance in difference Asian countries, where are lacking of outcome indicators surveillance data and public reporting.
This research provides valuable evidence to convince hospital managers, policy makers, and other stakeholders for development of their own local IPC strategies in terms of WHO recommendations. Furthermore, the gaps of IPC identified by this research may also reflect the same situations in other Asian countries. Policy makers should tailor and prioritize on important core/key components implementation in terms of local socioeconomic status and medical resources.
BIBLIOGRAPHY
1. Wang J, Liu F, Tartari E, Huang J, Harbarth S, Pittet D, et al. The Prevalence of Healthcare-Associated Infections in Mainland China: A Systematic Review and Meta-analysis. Infect Control Hosp Epidemiol 2018;39:701-9.
2. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 2011;377:228-41.
3. Bagheri Nejad S, Allegranzi B, Syed SB, Ellis B, Pittet D. Health-care-associated infection in Africa: a systematic review. Bull World Health Organ 2011;89:757-65.
4. Ling ML, Apisarnthanarak A, Madriaga G. The Burden of Healthcare-Associated Infections in Southeast Asia: A Systematic Literature Review and Meta-analysis.
Clin Infect Dis 2015;60:1690-9.
5. Bates DW, Larizgoitia I, Prasopa-Plaizier N, Jha AK. Global priorities for patient safety research. BMJ 2009;338:b1775.
6. Burke JP. Infection control - a problem for patient safety. N Engl J Med 2003;348:651-6.
7. European Center for Disease Prevention and Control. Point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals. Stockholm: ECDC. 2013.
8. Allegranzi B, Kilpatrick C, Storr J, Kelley E, Park BJ, Donaldson L. Global infection prevention and control priorities 2018-22: a call for action. Lancet Glob Health 2017;5:e1178-e80.
9. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al.
Multistate point-prevalence survey of health care-associated infections. N Engl J Med 2014;370:1198-208.
10. De Angelis G, Murthy A, Beyersmann J, Harbarth S. Estimating the impact of healthcare-associated infections on length of stay and costs. Clin Microbiol Infect 2010;16:1729-35.
11. Wang J, Liu F, Tan JBX, Harbarth S, Pittet D, Zingg W. Implementation of infection prevention and control in acute care hospitals in Mainland China - a systematic review. Antimicrob Resist Infect Control 2019;8:32.
12. Apisarnthanarak A, Mundy LM, Tantawichien T, Leelarasamee A. Infection Prevention and Control in Asia: Current Evidence and Future Milestones. Clin Infect Dis 2017;64(suppl_2):S49-s50.
13. Li Y, Huai Y, Varma J, Rao C. Healthcare-associated infection in mainland China:
a systematic review of point prevalence survey literature. ID Week: San Diego, CA; 2012.
14. Wang J, Hu J, Harbarth S, Pittet D, Zhou M, Zingg W. Burden of healthcare-associated infections in China: results of the 2015 point prevalence survey in Dong Guan City. J Hosp Infect 2017;96:132-8.
15. Zingg W, Huttner BD, Sax H, Pittet D. Assessing the burden of healthcare-associated infections through prevalence studies: what is the best method?
Infect Control Hosp Epidemiol 2014;35:674-84.
16. Ministry of Health of People’s Republic of China. Nosocomial Infection Management Method (Decree No.48) (in Chinese). 2006. Available at:
http://www.gov.cn/flfg/2006-07/25/content_344886.htm [last accessed 7 January 2020].
17. Li C, Wen X, Ren N, Zhou P, Huang X, Gong R, et al. Point-prevalence of healthcare-associated infection in china in 2010: a large multicenter epidemiological survey. Infect Control Hosp Epidemiol 2014;35:1436-7.
18. National Health Commission of the People's Republic of China. Standard for nosocomial infection surveillance in China WS/T312-2009 (in Chinese). Available at: http://www.nhc.gov.cn/wjw/index.shtml [last accessed 7 January 2020].
19. Cassini A, Hogberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015:
a population-level modelling analysis. Lancet Infect Dis 2019;19:56-66.
20. Temkin E, Fallach N, Almagor J, Gladstone BP, Tacconelli E, Carmeli Y.
Estimating the number of infections caused by antibiotic-resistant Escherichia coli and Klebsiella pneumoniae in 2014: a modelling study. Lancet Glob Health 2018;6:e969-e79.
21. European Centre for Disease Prevention and Control. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2017.
Stockholm: ECDC; 2018.
22. Stewardson AJ, Allignol A, Beyersmann J, Graves N, Schumacher M, Meyer R, et al. The health and economic burden of bloodstream infections caused by antimicrobial-susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro Surveill 2016;21: pii=30319.
23. Rohde AM, Zweigner J, Wiese-Posselt M, Schwab F, Behnke M, Kola A, et al.
Incidence of infections due to third generation cephalosporin-resistant Enterobacteriaceae - a prospective multicentre cohort study in six German university hospitals. Antimicrob Resist Infect Control 2018;7:159.
24. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al. Epidemiology of
Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network. Antimicrob Agents Chemother 2018;62.
25. World Health Organization. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016-2017. Geneva: WHO; 2017.
26. European Centre for Disease Prevention and Control. Antimicrobial resistance (AMR) reporting protocol - European Antimicrobial Resistance Surveillance Network (EARS-Net) surveillance data. Stockholm: ECDC; 2017.
27. Heymann DL, Rodier G. Global surveillance, national surveillance, and SARS.
Emerg Infect Dis 2004;10:173-5.
28. Asian Scientist Magazine. The state of infectious disease control in Post-SARS China. Available at:
https://www.asianscientist.com/2017/04/health/sars-prevention-control-china/ [last accessed 7 January 2020].
29. National Health Commission of the People’s Republic of China. China Antimicrobial Resistance Surveillance System (in Chinese). Available at:
http://www.carss.cn/ [last accessed 7 January 2020].
30. Hu F, Guo Y, Zhu D, Wang F, Jiang X, Xu Y, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET surveillance program, 2017 (in Chinese). Chin J Infect Chemother 2018;18:241-251.
31. Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, et al. Hospital organisation, management, and structure for prevention of
health-care-associated infection: a systematic review and expert consensus. Lancet Infect Dis 2015;15:212-24.
32. World Health Organization. Guidelines on core components of infection
prevention and control programmes at the national and acute health care facility level. 2016. Available at: http://www.who.int/gpsc/core-components.pdf [last accessed 7 January 2020].
33. Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. Antimicrob Resist Infect Control 2017;6:6.
34. National Health Commission of the People’s Republic of China. Accreditation regulation of control and prevention of healthcare-associated infection in hospital (WS/T 592 - 2018) (in Chinese). 2018. Available at:
http://www.nhc.gov.cn/ewebeditor/uploadfile/2018/07/20180704110307810.pdf [last accessed 7 January 2020].
35. Ren N, Wen X, Wu A. Nationwide cross-sectional survey on healthcare-associated infection in 2014 (in Chinese). Chin J Infect Control 2016;15:83-7.
36. Wang J. The challenges of antimicrobial resistance surveillance in China. Am J Infect Control 2019;47:1403-4.
37. Organization for Economic Co-operation and Development. Health at a glance, 2015. Israel Ministry of Health website. Available at:
https://www.health.gov.il/publicationsfiles/healthataglance2015.pdf [last accessed 7 January 2020].
38. Wang Y, Zhang X, Li S, Guo Y, Liu Q, Wang Y. Comparative analysis of hospital
beds resource utilization and average days of stay between China and aboard (in Chinese). Chin J Hosp Admin 2016;32:361-364.
39. Weiss AJ, Elixhauser A. Overview of Hospital Stays in the United States, 2012:
Statistical Brief #180. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: US Agency for Healthcare Research and Quality; 2006.
40. Jia H, Hou T, Li W, Ma H, Liu W, Yang Y, et al. Economic loss due to healthcare-associated infection in 68 general hospitals in China (in Chinese). Chin J Infect Control 2016;15:637-641.
41. Health expenditure in 2016. World Bank website. Available at:
https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?end=2016&locations
=CN&start=2000 [last accessed 7 January 2020].
42. Health expenditure per capita in China in 2016. World Bank website. Available at:https://data.worldbank.org/indicator/SH.XPD.CHEX.PC.CD?end=2016&locatio ns=CN&most_recent_value_desc=true&start=2000 [last accessed 7 January 2020].
43. Anand S, Fan VY, Zhang J, Zhang L, Ke Y, Dong Z, et al. China's human
resources for health: quantity, quality, and distribution. Lancet 2008;372:1774-81.
44. Dongguan Municipal Health Bureau. The budget statement of Ministry of Health and family planning bureau in Dongguan City in 2016 (in Chinese). Available at:
http://dghb.dg.gov.cn/ [last accessed 7 January 2020].
45. Dongguan Municipal Health Bureau. The public statistical information on the development of medical and healthcare service in Dongguan City (in Chinese).
Available at: http://dghb.dg.gov.cn/ [last accessed 7 January 2020].
46. Zhang Y, Zhang J, Wei D, Yang Z, Wang Y, Yao Z. Annual surveys for point-prevalence of healthcare-associated infection in a tertiary hospital in Beijing, China, 2012-2014. BMC Infect Dis 2016;16:161.
47. Xie DS, Xiong W, Xiang LL, Fu XY, Yu YH, Liu L, et al. Point prevalence surveys of healthcare-associated infection in 13 hospitals in Hubei Province, China, 2007-2008. J Hosp Infect 2010;76:150-5.
48. Ministry of Health of the People’s Republic of China Diagnostic criteria for
nosocomial infections. Chin Med J 2001;81:314–320.
49. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6(7):e1000097.
50. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP.
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-7.
51. Du M, Xing Y, Suo J, Liu B, Jia N, Huo R, et al. Real-time automatic hospital-wide surveillance of nosocomial infections and outbreaks in a large Chinese tertiary hospital. BMC Med Inform Decis Mak 2014;14:9.
52. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. M100-28th editions in 2017. CLSI, Wayne, PA, USA, 2017.
53. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:
an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81.
54. Zingg W, Castro-Sanchez E, Secci FV, Edwards R, Drumright LN, Sevdalis N, et al. Innovative tools for quality assessment: integrated quality criteria for review of multiple study designs (ICROMS). Public Health 2016;133:19-37.
55. Liu JY, Wu YH, Cai M, Zhou CL. Point-prevalence survey of healthcare-associated infections in Beijing, China: a survey and analysis in 2014. J Hosp Infect 2016;93:271-9.
56. Tao XB, Qian LH, Li Y, Wu Q, Ruan JJ, Cai DZ, et al. Hospital-acquired infection rate in a tertiary care teaching hospital in China: a cross-sectional survey
involving 2434 inpatients. Int J Infect Dis 2014;27:7-9.
57. World Health Organization. Report on the Burden of Endemic Health Care-Associated Infection Worldwide. 2011. Available at:
apps.who.int/iris/bitstream/10665/80135/1/9789241501507_eng.pdf?ua=1 [last
accessed 7 January 2020].
58. Thu TA, Hung NV, Quang NN, Archibald LK, Thuy le TT, Harun Or R, et al. A point-prevalence study on healthcare-associated infections in Vietnam: public health implications. Infect Control Hosp Epidemiol 2011;32:1039-41.
59. Izquierdo-Cubas F, Zambrano A, Frometa I, Gutierrez A, Bastanzuri M, Guanche H, et al. National prevalence of nosocomial infections. Cuba 2004. J Hosp Infect 2008;68:234-40.
60. Xiao Y, Li L. The Actions of China in Containing Antimicrobial Resistance.
Available at:
http://www.globalhealthdynamics.co.uk/wp-content/uploads/2015/05/07_Xiao-Li.pdf [last accessed 7 January 2020].
61. Wang Z, Zhang H, Han J, Xing H, Wu MC, Yang T. Deadly Sins of Antibiotic Abuse in China. Infect Control Hosp Epidemiol 2017;38:758-9.
62. Li Y, Xu J, Wang F, Wang B, Liu L, Hou W, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff (Millwood) 2012;31:1075-82.
63. Sun B. Nosocomial infection in China: Management status and solutions. Am J Infect Control 2016;44:851-2.
64. Zhou Y, Zhang D, Chen Y, Zhou S, Pan S, Huang Y, et al. Healthcare-associated infections and Shanghai clinicians: a multicenter cross-sectional study. PLoS One 2014;9:e105838.
65. Zingg W, Hopkins S, Gayet-Ageron A, Holmes A, Sharland M, Suetens C.
Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. Lancet Infect Dis 2017;17:381-9.
66. Sohn AH, Garrett DO, Sinkowitz-Cochran RL, Grohskopf LA, Levine GL, Stover BH, et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: Results from the first national point-prevalence survey. J Pediatr 2001;139:821-7.
67. Li G, Zhu D, Wang F, Hu Z, Li Q, Sun Z, et al. The distribution and antibiotic resistance of clinical isolates from blood culture in 2012 CHINET surveillance
program in China (in Chinese). Chin J Infect Chemother 2014;14:474-481.
68. Wang Y, Guan Z, Yan P, Sheng B, Ni X. Distribution and antimicrobial resistance of clinically isolated bacteria in a hospital from 2013 to 2018 (in Chinese). Chin J Infect Control 2019;18:538-545.
69. Hu F, Zhu D, Wang F, Wang M. Current Status and Trends of Antibacterial Resistance in China. Clin Infect Dis 2018;67(suppl_2):S128-s34.
70. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections:
epidemiology, clinical manifestations, and optimal management. Infect Drug Resist 2015;8:217-30.
71. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, et al.
Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. J Antimicrob Chemother 2013;68 Suppl 1:i7-22.
72. Yin X, Song F, Gong Y, Tu X, Wang Y, Cao S, et al. A systematic review of antibiotic utilization in China. J Antimicrob Chemother 2013;68:2445-52.
73. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health care settings in China. JAMA Intern Med 2014;174:1914-20.
74. Del Mar CB, Scott AM, Glasziou PP, Hoffmann T, van Driel ML, Beller E, et al.
Reducing antibiotic prescribing in Australian general practice: time for a national strategy. Med J Aust 2017;207:401-6.
75. Robert J, Pantel A, Merens A, Lavigne JP, Nicolas-Chanoine MH. Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12. J Antimicrob Chemother 2014;69:2706-12.
76. Clack L, Zingg W, Saint S, Casillas A, Touveneau S, da Liberdade Jantarada F, et al. Implementing infection prevention practices across European hospitals: an in-depth qualitative assessment. BMJ Qual Saf 2018;27:771-80.
77. Haley RW, Culver DH, White JW, Morgan WM, Emori TG, Munn VP, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol 1985;121:182-205.
78. Zhang Y, Zhang H, Jin F, Zhang J. Current status of full-time staff of nosocomial infections control in Gansu province (in Chinese). Chin J Nosocomiol
2013;23:3448-3449.
79. Zhang Z, Han M, Yang Z, Wei Q, Wang X, Wei Q, et al. Current situation of full-time healthcare-associated infection management staff in Xianyang City of Shaanxi Province (in Chinese). Chin J Infect Control 2017;16:635-638.
80. Liu S, Li C, Li L, Hou T, Ding L, Liu W, et al. Development of
healthcare-associated infection management organizations in China in the past 30 years (in Chinese). Chin J Infect Control 2016;15:648-653.
81. Yuan CT, Dembry LM, Higa B, Fu M, Wang H, Bradley EH. Perceptions of hand hygiene practices in China. J Hosp Infect 2009;71:157-62.
82. Hansen S, Schwab F, Zingg W, Gastmeier P. Process and outcome indicators for infection control and prevention in European acute care hospitals in 2011 to 2012 - Results of the PROHIBIT study. Euro Surveill 2018;23:pii=1700513.
83. Ren N, Wen X, Fu C, Li L, Hou T, Ding L, et al. Development and changing trend in monitoring of healthcare-associated infection in China (in Chinese). Chin J Infect Control 2016;15:642-647.
84. Zingg W, Mutters NT, Harbarth S, Friedrich AW. Education in infection control: A need for European certification. Clin Microbiol Infect 2015;21:1052-6.
85. European Committee on Infection Control. EUCIC launches a European training programme in Infection Prevention and Control in healthcare settings. 2018.
Available at:
https://www.escmid.org/fileadmin/src/media/PDFs/3Research_Projects/EUCIC/W EB_EUCIC_Groningen_2018.pdf [last accessed 7 January 2020].
86. Wu A, Huang X, Li L, Gong Y, Liu C, Wang L, et al. Guideline for professional training about managing of healthcare associated infections WS/T 525-2016 (in Chinese). Chin J Infect Control 2017;16:94-97.
87. Wang X, Cai L, Yu R, Huang W, Zong Z. ICU-Onset Clostridium difficile infection in a university hospital in China: a prospective cohort study. PLoS One
2014;9:e111735.
88. Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, et al. Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China. Anaerobe 2014;30:65-9.
89. Ministry of Health of People's Republic of China. The management approach of clinical application of antibiotics use (in Chinese). Chin J Frontiers of Med Sci 2013;5:9-14.
90. Hu F, Guo Y, Zhu D, Wang F, Jiang X, Xu Y, et al. CHINET surveillance of bacterial resistance across China: report of the results in 2016. Chin J Infect Chemother 2017;17:481-491.
91. Zingg W, Metsini A, Gardiol C, Balmelli C, Behnke M, Troillet N, et al.
Antimicrobial use in acute care hospitals: national point prevalence survey on healthcare-associated infections and antimicrobial use, Switzerland, 2017. Euro Surveill 2019;24:pii=1900015.
92. Rosenthal VD. Device-associated nosocomial infections in limited-resources countries: findings of the International Nosocomial Infection Control Consortium (INICC). Am J Infect Control 2008;36:S171.e7-12.
93. Wang J, Mo Q, Qi K. Device-associated healthcare-associated infection in intensive care unit of a university hospital in China: a descriptive study. Chin J Infect Control 2016;15:902-6.
94. Wolkewitz M, Cooper BS, Palomar-Martinez M, Alvarez-Lerma F, Olaechea-Astigarraga P, Barnett AG, et al. Multiple time scales in modeling the incidence of infections acquired in intensive care units. BMC Med Res Methodol 2016;16:116.
ANNEXES
Article 1
- Wang J, Hu J, Harbarth S, Pittet D, Zhou M, Zingg W: Burden of healthcare-associated infections in China: results of the 2015 point prevalence survey in Dong Guan City. J Hosp Infect 2017, 96(2):132-138.
https://www.ncbi.nlm.nih.gov/pubmed/28325579 Article 2
- Wang J, Liu F, Tartari E, Huang J, Harbarth S, Pittet D, Zingg W: The Prevalence of Healthcare-Associated Infections in Mainland China: A Systematic Review and Meta-analysis. Infect Control Hosp Epidemiol 2018, 39(6):701-709.
https://www.ncbi.nlm.nih.gov/pubmed/29655388 Article 3
- Wang J, Zhou M, Huang G, Guo Z, Sauser J, Metsini A, Pittet D, Zingg W:
Antimicrobial resistance in Southern China: Results of prospective surveillance in Dong Guan City, 2017. J Hosp Infect 2020, 105(2):188-196.
https://pubmed.ncbi.nlm.nih.gov/32243952/
Article 4
- Wang J, Liu F, Tan JBX, Harbarth S, Pittet D, Zingg W: Implementation of infection prevention and control in acute care hospitals in Mainland China - a systematic review. Antimicrob Resist Infect Control 2019, 8:32.
https://www.ncbi.nlm.nih.gov/pubmed/30792854 Article 5
- Wang J, Zhou M, Hesketh T, Kritsotakis EI: Clinical impact of third generation cephalosporin-resistance in Enterobacteriaceae infections: a multicenter cohort study in Southern China. Am J Infect Control 2020 (Under Review)